Aslan Pharmaceuticals Limited Quick Ratio (ASLN) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aslan Pharmaceuticals Limited  (NASDAQ: ASLN)

Aslan Pharmaceuticals Limited's Quick Ratio

ASLN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2023, Quick Ratio deteriorated to 0.86 below Aslan Pharmaceuticals Limited's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Aslan Pharmaceuticals Limited in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 1931 to 2380.

Explain Quick Ratio?
How much Cash & cash equivalents ASLN´s has?
What are ASLN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ASLN Quick Ratio (Dec 31 2023)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change -16.38 % -16.38 % -32.79 % -16.38 % -3.89 %
Y / Y Cash & cash equivalent Change -62.65 % -62.65 % -33.51 % -62.65 % -36.89 %
Quick Ratio MRQ 0.86 0.86 1.67 0.86 1.92
ASLN's Total Ranking # 2380 # 1931 # 0 # 0 # 1575
Seq. Current Liabilities Change 0 % 1.32 % -1.3 % -16.38 % 0 %
Seq. Cash & cash equivalent Change 0 % -48.09 % 92.66 % -62.65 % 0 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 438
Healthcare Sector # 798
Overall Market # 2380


Quick Ratio Statistics
High Average Low
6.19 1.91 0.56
0   (Sep 30 2019)




Financial Statements
Aslan Pharmaceuticals Limited's Current Liabilities $ 25 Millions Visit ASLN's Balance sheet
Aslan Pharmaceuticals Limited's Cash & cash equivalent $ 21 Millions Visit ASLN's Balance sheet
Source of ASLN's Sales Visit ASLN's Sales by Geography


Cumulative Aslan Pharmaceuticals Limited's Quick Ratio

ASLN's Quick Ratio for the trailling 12 Months

ASLN Quick Ratio

 (Dec 31 2023)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -21.15 % -18.06 % -15.03 % 13.08 % 16.33 %
Y / Y Cash & cash equivalent TTM Growth -54.93 % -47.15 % -41.1 % -40.66 % -36.3 %
Quick Ratio TTM 1.06 1.35 1.62 1.63 1.85
Total Ranking TTM # 4070 # 3846 # 0 # 0 # 1374
Seq. Current Liabilities TTM Growth -4.68 % -4.47 % -9.91 % -3.87 % -0.95 %
Seq. Cash & cash equivalent TTM Growth -25.4 % -20.26 % -10.49 % -15.35 % -12.53 %

Quick ratio ranking by company, industry and sector >> Back to ASLN Financial Strength Comparisons >> Go to Compare ASLN Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ASLN's Current Liabilities to $24.80 millions, cumulative Quick Ratio to 1.06 below the ASLN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 490 other companies have achieved higher Quick Ratio than Aslan Pharmaceuticals Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 3846 to 4070.

Explain Quick Ratio?
How much Cash & cash equivalents ASLN´s has?
What are ASLN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 491
Healthcare Sector # 1002
Within the Market # 4070


trailing twelve months Quick Ratio Statistics
High Average Low
2.92 1.7 0.79
(Dec 31 2021)   (Dec 31 2020)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Cdt Equity Inc   2.35 $ 4.228  Millions$ 1.801  Millions
Synlogic Inc   2.34 $ 47.746  Millions$ 20.404  Millions
Aptevo Therapeutics Inc   2.34 $ 16.904  Millions$ 7.224  Millions
Sarepta Therapeutics Inc   2.33 $ 1,676.250  Millions$ 718.689  Millions
Traws Pharma inc   2.29 $ 20.559  Millions$ 8.994  Millions
Vincerx Pharma Inc   2.28 $ 12.782  Millions$ 5.605  Millions
Imunon Inc   2.27 $ 15.696  Millions$ 6.906  Millions
Theravance Biopharma inc   2.19 $ 191.486  Millions$ 87.437  Millions
Curevac N v   2.19 $ 456.571  Millions$ 208.756  Millions
Revelation Biosciences Inc   2.15 $ 11.992  Millions$ 5.565  Millions
Puretech Health Plc  2.12 $ 202.827  Millions$ 95.477  Millions
Hutchmed china Limited  2.12 $ 887.401  Millions$ 419.367  Millions
Gt Biopharma Inc   2.11 $ 13.972  Millions$ 6.633  Millions
Genprex Inc   2.07 $ 6.738  Millions$ 3.254  Millions
Ultragenyx Pharmaceutical Inc   2.06 $ 577.209  Millions$ 280.437  Millions
Spero Therapeutics Inc   2.05 $ 76.333  Millions$ 37.153  Millions
Insmed Inc  2.03 $ 780.447  Millions$ 384.774  Millions
Tvardi Therapeutics Inc   2.02 $ 51.775  Millions$ 25.592  Millions
Atrium Therapeutics Inc   2.02 $ 185.082  Millions$ 91.729  Millions
Pmgc Holdings Inc   2.00 $ 1.179  Millions$ 0.588  Millions
Oragenics Inc   1.95 $ 3.484  Millions$ 1.788  Millions
Ampio Pharmaceuticals inc   1.95 $ 4.089  Millions$ 2.102  Millions
Nextcure Inc   1.90 $ 13.082  Millions$ 6.883  Millions
Immunic Inc   1.89 $ 46.674  Millions$ 24.729  Millions
Unity Biotechnology Inc   1.84 $ 43.201  Millions$ 23.456  Millions
Geovax Labs Inc   1.84 $ 6.464  Millions$ 3.520  Millions
Adlai Nortye Ltd  1.81 $ 91.492  Millions$ 50.447  Millions
Catalyst Pharmaceuticals Inc   1.81 $ 137.636  Millions$ 76.063  Millions
Macrogenics Inc   1.80 $ 100.956  Millions$ 56.108  Millions
Alzamend Neuro Inc   1.79 $ 5.141  Millions$ 2.870  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.